坎格列净治疗2型糖尿病的研究(3)
[3]Di LL，Mangano M，Ronco C，et al.The treatment of type 2 diabetes mellitus in patients with chronic kidney disease：what to expect from new oral hypoglycemic agents[J].Diabetes Metab Syndr，2017(Suppl 1)：S295-S305.
[4]Choi CI.Sodium-glucose cotransporter 2(SGLT2)inhibitors from natural products：discovery of next-generation antihyperglycemic agents[J].Molecules，2016，21(9)：1136.
[5]胡秀卓，吕莉.钠-葡萄糖共转运体2抑制剂在治疗2型糖尿病中的应用[J].中国临床药理学与治疗学，2015，20(3)：338-343.
, http://www.100md.com
[6]谷光宇，郑少雄.钠-葡萄糖协同转运蛋白2抑制剂-糖尿病治疗新途径[J].中国实用内科杂志，2014，34(10)：962-968.
[7]Mamidi RN，Cuyckens F，Chen J，et al.Metabolism and excretion of canagliflozin in mice， rats， dogs， and humans[J].Drug Metab Dispos，2014，42(5)：903-916.
[8]Sha S，Devineni D，Ghosh A，et al.Pharmacodynamic effects of canagliflozin，a sodium glucose co-transporter 2 inhibitor，from a randomized study in patients with type 2 diabetes[J].PLoS One，2014，9(8)：e105638.
, 百拇医药
[9]Whalen K，Miller S，Onge ES.The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes[J].Clin Ther，2015，37(6)：1150-1166.
[10]Bode B，Stenlf K，Harris S，et al.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J].Diabetes Obes Metab，2015，17(3)：294-303.
[11]Qiu R，Gapuano G，Meininger G.Efficacy and safety of twice-daily treatment with canagliflozin，a sodium glucose co-transporter 2 inhibitor，added on to metformin monotherapy in patients with type 2 diabetes mellitus[J].J Clin Transl End Ocrinol，2014，1(2)：54-60.
, http://www.100md.com
[12]Inagaki N，Kondo K，Yoshinari T，et al.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes：a 52-week open-label study[J].J Diabetes Invest，2015，6(2)：210-218.
[13]Gilbert RE，Weir MR，Fioretto P，et al.Impact of age and estimated glomerular filtration rate on the glycemic efficacy and safety of canagliflozin：A pooled analysis of clinical studies[J].Can J Diabetes，2016，40(3)：247-257.
, 百拇医药
[14]Neal B，Perkovic V，de Zeeuw D，et al.Efficacy and safety of canagliflozin， an inhibitor of sodium-glucose cotrans-porter 2， when used in conjunction with insulin therapy in patients with type 2 diabetes[J].Diabetes Care，2015，38(3)：403-411.
[15]Yang XP，Lai D，Zhong XY，et al.Efficacy and safety of canagliflozin in subjects with type 2 diabetes： systematic review and meta-analysis[J].Eur J Clin Pharmacol，2014，70(10)：1149-1158.
[16]Leiter LA，Yoon KH，Arias P，et al.Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin： a randomized， double-blind， phase 3 study[J].Diabetes Care，2015，38(3)：355-364.
, http://www.100md.com
[17]Weir MR，Januszewicz A，Gilbert RE，et al.Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus[J].J Clin Hypertens (Greenwich)，2014，16(12)：875-882.
[18]紀立农，郭立新，郭晓蕙，等.钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志，2016，24(10)：865-870.
[19]Nyirjesy P，Sobel JD，Fung A，et al.Genital mycotic infections with canagliflozin， a sodium glucose co-transporter 2 inhibitor， in patients with type 2 diabetes mellitus： a pooled analysis of clinical studies[J].Curr Med Res Opin，2014，30(6)：1109-1119.
, http://www.100md.com
[20]邹寿涛.口服降血糖新药-坎格列净[J].中南药学，2014，12(12)：1277-1279.
[21]Reilly TP，Graziano MJ，Janovitz EB，et al.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin， an inhibitor of sodium-glucose co-transporter 2， in the treatment of type 2 diabetes mellitus[J].Diabetes Ther，2014，5(1)：73-96.
收稿日期：2019-2-13;修回日期：2019-2-23
编辑/杜帆, http://www.100md.com(刘金婷)
[4]Choi CI.Sodium-glucose cotransporter 2(SGLT2)inhibitors from natural products：discovery of next-generation antihyperglycemic agents[J].Molecules，2016，21(9)：1136.
[5]胡秀卓，吕莉.钠-葡萄糖共转运体2抑制剂在治疗2型糖尿病中的应用[J].中国临床药理学与治疗学，2015，20(3)：338-343.
, http://www.100md.com
[6]谷光宇，郑少雄.钠-葡萄糖协同转运蛋白2抑制剂-糖尿病治疗新途径[J].中国实用内科杂志，2014，34(10)：962-968.
[7]Mamidi RN，Cuyckens F，Chen J，et al.Metabolism and excretion of canagliflozin in mice， rats， dogs， and humans[J].Drug Metab Dispos，2014，42(5)：903-916.
[8]Sha S，Devineni D，Ghosh A，et al.Pharmacodynamic effects of canagliflozin，a sodium glucose co-transporter 2 inhibitor，from a randomized study in patients with type 2 diabetes[J].PLoS One，2014，9(8)：e105638.
, 百拇医药
[9]Whalen K，Miller S，Onge ES.The role of sodium-glucose co-transporter 2 inhibitors in the treatment of type 2 diabetes[J].Clin Ther，2015，37(6)：1150-1166.
[10]Bode B，Stenlf K，Harris S，et al.Long-term efficacy and safety of canagliflozin over 104 weeks in patients aged 55-80 years with type 2 diabetes[J].Diabetes Obes Metab，2015，17(3)：294-303.
[11]Qiu R，Gapuano G，Meininger G.Efficacy and safety of twice-daily treatment with canagliflozin，a sodium glucose co-transporter 2 inhibitor，added on to metformin monotherapy in patients with type 2 diabetes mellitus[J].J Clin Transl End Ocrinol，2014，1(2)：54-60.
, http://www.100md.com
[12]Inagaki N，Kondo K，Yoshinari T，et al.Efficacy and safety of canagliflozin alone or as add-on to other oral antihyperglycemic drugs in Japanese patients with type 2 diabetes：a 52-week open-label study[J].J Diabetes Invest，2015，6(2)：210-218.
[13]Gilbert RE，Weir MR，Fioretto P，et al.Impact of age and estimated glomerular filtration rate on the glycemic efficacy and safety of canagliflozin：A pooled analysis of clinical studies[J].Can J Diabetes，2016，40(3)：247-257.
, 百拇医药
[14]Neal B，Perkovic V，de Zeeuw D，et al.Efficacy and safety of canagliflozin， an inhibitor of sodium-glucose cotrans-porter 2， when used in conjunction with insulin therapy in patients with type 2 diabetes[J].Diabetes Care，2015，38(3)：403-411.
[15]Yang XP，Lai D，Zhong XY，et al.Efficacy and safety of canagliflozin in subjects with type 2 diabetes： systematic review and meta-analysis[J].Eur J Clin Pharmacol，2014，70(10)：1149-1158.
[16]Leiter LA，Yoon KH，Arias P，et al.Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin： a randomized， double-blind， phase 3 study[J].Diabetes Care，2015，38(3)：355-364.
, http://www.100md.com
[17]Weir MR，Januszewicz A，Gilbert RE，et al.Effect of canagliflozin on blood pressure and adverse events related to osmotic diuresis and reduced intravascular volume in patients with type 2 diabetes mellitus[J].J Clin Hypertens (Greenwich)，2014，16(12)：875-882.
[18]紀立农，郭立新，郭晓蕙，等.钠-葡萄糖共转运蛋白2(SGLT2)抑制剂临床合理应用中国专家建议[J].中国糖尿病杂志，2016，24(10)：865-870.
[19]Nyirjesy P，Sobel JD，Fung A，et al.Genital mycotic infections with canagliflozin， a sodium glucose co-transporter 2 inhibitor， in patients with type 2 diabetes mellitus： a pooled analysis of clinical studies[J].Curr Med Res Opin，2014，30(6)：1109-1119.
, http://www.100md.com
[20]邹寿涛.口服降血糖新药-坎格列净[J].中南药学，2014，12(12)：1277-1279.
[21]Reilly TP，Graziano MJ，Janovitz EB，et al.Carcinogenicity risk assessment supports the chronic safety of dapagliflozin， an inhibitor of sodium-glucose co-transporter 2， in the treatment of type 2 diabetes mellitus[J].Diabetes Ther，2014，5(1)：73-96.
收稿日期：2019-2-13;修回日期：2019-2-23
编辑/杜帆, http://www.100md.com(刘金婷)